Login to Your Account

Phase II Data Keep M-101 on Track for Pivotal Trials

By Cormac Sheridan
Staff Writer

Wednesday, September 11, 2013
With the start of a Phase III trial of its lead compound tinnitus drug AM-101 imminent, Auris Medical AG has completed a second Phase II trial, which further rounds out its understanding of how to administer the therapy.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription